Welcome to our dedicated page for SCIIU news (Ticker: SCIIU), a resource for investors and traders seeking the latest updates and insights on SCIIU stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SCIIU's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SCIIU's position in the market.
SC II Acquisition Corp (NASDAQ: SCIIU) priced an initial public offering of 15,000,000 units at $10.00 per unit, implying gross proceeds of $150,000,000. Units will begin trading on November 26, 2025 and closing is expected on November 28, 2025, subject to customary closing conditions.
Each unit contains one Class A ordinary share and one right to receive 1/5 of a Class A share upon consummation of an initial business combination. The underwriters have a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments. The sponsor is managed by Nukkleus (Nasdaq: NUKK).
